Suppression of tropomyosins (TMs), a family of actinbinding, microfilament-associated proteins, is a prominent feature of many transformed cells. Yet it is unclear whether downregulation of TMs occur in human tumors. We have investigated the expression of tropomyosin-1 (TM1) in human breast carcinoma tissues by in situ hybridization and immunofluorescence. TM1 mRNA and protein are readily detectable in normal mammary tissue. In contrast, TM1 expression is abolished in the primary human breast tumors. Expression of other TM isoforms, however, is variable among the tumors. The consistent and profound downregulation of TM1 suggests that TM1 may be a novel and useful biomarker of mammary neoplasms. These data also support the hypothesis that suppression of TM1 expression during the malignant conversion of mammary epithelium as a contributing factor of breast cancer. In support of this hypothesis, we show that the ability to suppress malignant growth properties of breast cancer cells is specific to TM1 isoform. Investigations into the mechanisms of TM1-induced tumor suppression reveal that TM1 induces anoikis (detachment induced apoptosis) in breast cancer cells. Downregulation of TM1 in breast tumors may destabilize microfilament architecture and confer resistance to anoikis, which facilitates survival of neoplastic cells outside the normal microenvironment and promote malignant growth.
Introduction
During neoplastic transformation, cells undergo numerous biochemical changes, some of which confer a selective advantage over their normal counterparts to facilitate malignant growth. These changes include mutational inactivation of tumor suppressor proteins, activation of oncogenes and other epigenetic events (Fearon and Vogelstein, 1990; Beckmann et al., 1997) . Elucidation of these causal molecular events is necessary to develop better tumor markers and identify effective targets for cancer treatment. A number of research groups have demonstrated that suppression of high-M r tropomyosin (TM) isoforms (tropomyosin-1 and tropomyosin-2) occurs in malignant cells, suggesting a role for these proteins in neoplastic transformation (Hendricks and Weintraub, 1981; Matsumura et al., 1983; Cooper et al., 1985; Bhattacharya et al., 1990) .
TMs are a family of actin-binding proteins that stabilize microfilaments and are expressed with a high degree of tissue specificity (Lin et al., 1997; Pawlak and Helfman, 2001 ). TMs may be broadly categorized into high-and low-M r species depending on their size. In nonmuscle cells, such as fibroblasts and epithelial cells, multiple high-M r TMs are expressed, which are referred to as isoforms TM1, TM2 and TM3; additionally, epithelial cells also express another protein designated as TM38. Similarly, smooth muscle cells express two TM isoforms, TM1 and TM2. Previous work from this laboratory has demonstrated that multiple TM isoforms are downregulated in human breast carcinoma cells (Bhattacharya et al., 1990) . More significantly, expression of TM1 was consistently abolished in most commonly studied breast cancer cell lines, indicating that loss of TM1 could be an important event in mammary carcinogenesis. This finding is in line with the general observations that most neoplastic cells exhibit altered cellular morphology and contain disorganized microfilaments, and that suppression of TM1 is a common biochemical event in cells transformed by diverse oncogenic modalities (Cooper et al., 1985) . We hypothesized that loss of TM1 results in the formation of disorganized microfilaments, which in turn, facilitate neoplastic conversion. Consistent with this hypothesis, TM1 reorganizes actin filaments and functions as a supp-ressor of malignant transformation (Prasad et al., 1993 (Prasad et al., , 1999 Braverman et al., 1996; Mahadev et al., 2002) .
Since many breast carcinoma cell lines lack TM1, we considered whether TM1 could serve as a potential tumor marker. Two previous studies, utilizing biochemical methods, have suggested that TM1 expression may be enhanced in breast tumors (Franzen et al., 1996 (Franzen et al., , 1997 . However, we believe that accurate assessment of TM1 expression in tissues by biochemical methods is difficult for several reasons. For example, (1) multiple TM proteins share extensive sequence homology; (2) TM1 is expressed in multiple cell types present in tissues. In addition to epithelial and stromal cells, smooth muscle cells of tumor vasculature express abundant amounts of TM1 and; (3) the lack of isoform-specific antibodies has rendered the accurate assessment of TM1 protein by immunohistochemistry in human tissues difficult. In this communication, we have investigated whether TM1 expression is altered in human breast carcinomas, and the isoform specific breast cancer suppression by TMs. We also report that inhibition of malignant growth of breast cancer cells by TM1 involves induction of anoikis.
Results
Since TM1 expression is consistently lost in breast cancer cells, and TM1 suppresses the malignant growth of breast cancer cells (Mahadev et al., 2002) , we have chosen to investigate changes in TM1 expression in breast cancer. We utilized in situ hybridization and immunofluorescence methods to validate the RNA probes and TM1-specific antibody (data not shown) using MCF10A and MCF-7 cells, which contain known TM profiles (Bhattacharya et al., 1990) . TM1 expression was detected in MCF-10A cells; MCF-7 cells, on the other hand, lacked TM1 mRNA and protein, in agreement with the Northern blotting data and twodimensional gel analyses.
TM1 mRNA expression is downregulated in breast cancer
To determine whether TM1 expression is altered in breast tumors, in situ hybridization was performed. Adjacent normal tissues from the breast cancer patients, as judged by gross examination and histology, were also used. TM1 expression was readily detectable by the intense labeling of silver grains in the normal ducts (Figure 1 ). Adjacent sections hybridized to the control sense probe lacked specific signal and pattern, and was diffuse and weak.
Analysis of the adjacent invasive tumor tissue revealed profound differences in TM1 expression compared to the normal tissue. The invasive breast tumor tissue lacked any detectable TM1 mRNA, and the signal obtained with the antisense probe and the control sense probe was essentially identical. The signal obtained with the antisense probe in tumor tissue was comparable to that obtained with the background signal. Analysis of five different normal ducts and malignant cells revealed significant differences between the tissues. The mean intensity, indicative of the abundance of TM1 mRNA in normal ducts, was 29.778.1 (mean7s.d.) after subtracting the background signal obtained with the sense probe. In contrast, TM1 mRNA levels in the tumor tissue corresponded to a mean value of 3.872.8 over the background. Thus, TM1 expression is profoundly suppressed in breast tumors.
Immunohistochemical analysis of TM1 expression in invasive breast cancer
To further evaluate changes in TM1 expression, we have performed immunohistochemistry on the same set of tissues used for in situ studies.
Immunofluorescence analysis of normal breast epithelium with a TM1-specific antibody (Mahadev et al., 2002) revealed specific staining of both myoepithelial and luminal epithelial layers of the ducts for TM1 (Figure 2a) . Omission of the primary antibody in the reaction (background) did not produce any detectable staining. Autofluorescence in the FITC channel revealed background signal that did not interfere with the TM1 signal.
Malignant breast epithelium, on the other hand, lacked any detectable TM1, and the signal intensity in the tumor area was equal to that obtained with omission of the primary antibody (Figure 2b) . The blood vessels present in the tumor, however, stained intensely with TM1 antibody, indicating that the lack of staining in tumor tissue was not due to the inability of the antibody Figure 1 TM1 mRNA expression in normal and malignant breast tissue: normal and malignant breast tissues were hybridized with antisense (top and middle panels) and sense TM1 probes (bottom panel), and developed as described in Materials and methods. Samples were photographed in bright field to view the tissue architecture, and in dark field to view the silver grains indicative of TM1 expression. H&E staining of the tissue, sense probe hybridization of tumor tissue are not depicted. Samples were photographed at Â 25 magnification to detect TM1. TM1 expression was undetectable in any of the 25 tumors tested, independent of any other parameters such as the stage, nodal status, hormone receptor status, proliferative index or HER2/neu status.
Quantitation of TM1 expression in tumor tissues revealed a significant decrease compared with the normal tissue. We measured relative luminosity in 10 normal and nine tumor tissue images, along with 14 background images taken from different tissues. Based on results from a mixed model, the adjusted mean levels of luminosity in normal tissues are 47.571.1, for tumor tissues 16.271.1, and the background signal is 15.371.1 (mean7s.e.). TM1 expression levels in normal tissues over the background are highly significant (Po0.0001). The difference in TM1 protein levels between normal and tumor tissues is highly significant (Po0.0001), indicating a profound downregulation of TM1 in breast tumors. However, the difference between tumor and the background signal was not significant (P ¼ 0.63). These results demonstrate that while normal mammary tissues express abundant quantities of TM1, the malignant breast tumors essentially lack TM1.
To investigate, whether in addition to TM1, other TMs are also downregulated in breast tumors, tissue sections were screened with a pan-TM antibody which reacts preferentially with the high-M r TMs, including TM1 (Bhattacharya et al., 1990; Mahadev et al., 2002) . The normal ducts were intensely stained with the pan-TM antibody, indicating the expression of TM1 and other TMs in both the basal and luminal epithelial cells ( Figure 3a) . In breast tumor specimens, however, the staining pattern was variable. In most tumors (19/25, 76%) no signal was detected, indicating lack of or low level of expression of TMs ( Figure 3b ; Table 1 ). Blood vessels present in tumor tissue intensely stained, demonstrating the reactivity of TM antibody.
In a significant number (6/25 samples; 24% of breast tumors; Table 1 ) of tumor tissues, the pan-TM antibody reactivity was readily evident by the intense staining of tumor tissues, indicating the expression of other TM proteins ( Figure 3c ). The same set of samples stained negative for TM1 expression in parallel experiments, indicating that TM1 was consistently abolished in breast tumors, and expression of other TMs was variable. The widespread suppression of TM1 in breast carcinomas and the ability of TM1 to inhibit malignant growth of breast cancer cells strengthens the hypothesis that TM1 is a tumor suppressor (Prasad et al., 1993, #5; Prasad et al., 1999, #6; Mahadev et al., 2002, #41) . Taken together, our findings suggest that the loss of TM1 expression is a crucial event that directly contributes to mammary carcinogenesis.
Isoform-specific suppression of malignant growth of breast cancer cells by TM1
Since both TM1 and TM2 share extensive sequence homology (Figure 4a ), and contrary to our findings (Braverman et al., 1996) , TM2 is suggested to function as a ras-suppressor (Janssen and Mier, 1997), we have tested the effect of restoration of TM2 in breast cancer cells. Stable expression of TM2 failed to inhibit the anchorage-independent growth of MCF-7 cells (Figure 4b ). Both parental MCF-7 cells and those Figure 2 Expression of TM1 protein in normal and malignant breast tissues: (a) TM1 is expressed in normal ducts. Tissue sections were stained with TM1-specific antibody, and TM1 staining was viewed with a rhodamine cube, or autofluorescence was recorded through FITC cube. A parallel section was processed by omitting the primary antibody for negative control (background). H&E staining of the tissue sample is also shown. (b) Tumor tissue lacks expression of TM1: breast tumor stained with TM1-specific antibody (TM1 expression), negative control (background) and nuclear morphology along with H&E staining are shown. While the tumor area lacks TM1 staining, a blood vessel in the tumor reacts strongly, serving as a positive control for TM1 staining. Â 25 magnification expressing TM2 formed colonies in agar, indicating that TM2 is not a suppressor of transformation in breast cancer cells.
Adenoviral transduction of TM1, on the other hand, suppresses anchorage-independent growth of MCF-7 cells (Figure 4c ). We have transduced MCF-7 cells using the AdEasy system, which allows for coexpression of green fluorescent protein (GFP) along with wild-type TM1 (AdTM1). TM1 expressing MCF-7 cells, visualized by GFP expression, failed to grow under anchorage-independent conditions, while those not infected with AdTM1 virus, or those transduced with the control virus expressing only GFP (AdGFP), grew aggressively. Since MCF-7 cells grow as clumps, during the initial culture period, GFP expressing clumps were evident, which diminished with time. At the end of 20 days of culture, essentially all of the TM1 expressing cells died, as observed by lack of GFP expressing cells. MCF-7 cells transduced with AdGFP virus yielded 4870 colonies of cells positive for GFP in this representative experiment. In contrast, transduction of MCF-7 cells with TM1 resulted in a 50% decrease in total number of colonies compared to those infected with the control virus, reflecting the 50% efficiency of the adenoviral transduction in this experiment. These data further support the isoform specificity of TM1-mediated suppression of the malignant growth properties of breast cancer cells (Braverman et al., 1996) .
TM1 induces anoikis in breast cancer cells
In efforts to better understand TM1-mediated tumor suppression, we have investigated whether TM1 modulates cell cycle. As depicted in Figure 5a , asynchronous populations of MCF-7/TM1 cells contained significantly lower fraction of cells in S phase compared to MCF-7 cells. The number of cells in G 2 -M phase was slightly higher in MCF-7/TM1 cells than in the parental cells. Furthermore, 5-bromo-2 0 -deoxyuridine (BrdU) incorporation studies (Figure 5b ) also revealed that TM1 expression decreases the S phase in MCF-7 cells. The S-phase fraction values for MCF-7 cells (34.4%) were significantly higher than with MCF-7/TM1 (20.7%), indicating a lower rate of DNA synthesis. Interestingly, a significant number of MCF-7/TM1 cells, although were in S phase (based on DNA content), remained 'inactive' as judged by BrdU incorporation (Figure 5b) . Thus, the slower monolayer growth of MCF-7/TM1 cells observed in previous studies (Mahadev et al., 2002) is due to a decrease in S-phase fraction, and does not fully explain tumor suppression by TM1.
One of the hallmarks of malignant growth is to acquire resistance to undergo apoptosis when deprived of normal cell-matrix interactions, also known as anoikis (Frisch and Screaton, 2001; Stupack and Cheresh, 2002) . TM1 restoration in many transformed cells profoundly suppresses anchorage-independent growth, indicating that TM1 resensitizes malignant cells to adhesion-dependent survival. Therefore, we have further investigated whether TM1-mediated tumor suppression involves anoikis. MCF-7/TM1 and MDA MB 231/TM1 were cultured in suspension and tested for cell survival and apoptosis. Unmodified MCF-7 cells, and those transduced with TM1 were cultured on polyHEMA-coated dishes to prevent adhesion to substratum, and examined nuclear morphology to determine whether TM1 induces anoikis. MCF-7/TM1 cells, when cultured in suspension, exhibited fragmented and dense nuclei consistent with apoptosis, indicating that TM1 induces anoikis in MCF-7 cells (Figure 6a ). However, there was no evidence of apoptosis in parallel suspension cultures of MCF-7 cells (Figure 6a ), or adherent cultures of MCF-7 and MCF-7/ TM1 cells (data not shown). Next, we investigated whether MCF-7/TM2 cells undergo anoikis. Unlike, MCF-7/TM1 cells, MCF-7/TM2 cells had exhibited resistance to anoikis, as determined by nuclear morphology (Figure 6a ). Consistent with this result, parental MCF-7 and MCF-7/TM2 cells did not accumulate DNA in subG 0 -G 1 fraction of cell cycle, which is indicative of apoptosis, and the cell cycle pattern was comparable to that of the adherent cells (data not shown). These results indicate that TM1, but not TM2, sensitize breast cancer cells to detatchmentinduced apoptosis, which is in agreement with the results of anchorage-independent growth experiments ( Figure 4a ).
To further examine whether TM1-mediated tumor suppression of breast cancer involves anoikis or it is a cell-type-specific effect in MCF-7 cells, we tested the ability of TM1 to sensitize MDA MB 231 cells to undergo detachment-induced apoptosis. As shown in Figure 6b , MDA MB 231/TM1 cells were undergoing massive cell death (70%) by 24 h of suspension culture, while unmodified MDA MB 231 cells exhibited background apoptosis (8.3%). A likely reason for rapid induction of anoikis by TM1 in MDA MB 231 cells is that MCF-7 cells exhibit stronger cell-cell adhesion due to the expression of E-cadherin (Sommers et al., 1994) . Since cell-cell interactions also provide survival signals, the onset of anoikis may have been delayed in MCF-7 cells expressing TM1. Moreover, TM1 expression appears to result in increased cytoskeletal association of E-cadherin complex (Mahadev et al., 2002) , presumably leading to enhanced cell-cell interactions.
Since TM1 expression induces profound and rapid anoikis in MDA MB 231 cells, we next examined the kinetics of induction of anoikis by TM1 by flow cytometry, and determined the accumulation of DNA in subG 0 -G 1 fraction of cell cycle. By 6 h of culture in suspension, TM1 expressing cells accumulated 34% of DNA in subG 0 -G 1 fraction, (Figure 6b and c) . In contrast, MDA MB 231 cells did not contain any DNA in the subG 0 -G 1 fraction, indicating normal growth (Figure 6a ). The subG 0 -G 1 phase increased with time in suspension cultures of MDA MB 231/TM1 cells reaching 70%. MDA MB 231 cells, in contrast, exhibited normal cell cycle pattern and significantly lower (about 13%) DNA in subG 0 -G 1 fraction compared to TM1 expressing cells by 24 h (Figure 6c ). Adherent cultures of both cell types, however, contained background (r5%) quantities of fragmented DNA (boxes marked 'adh', Figure 6c ). These data indicate that TM1 induces anoikis in breast cancer cells, and resensitization of the tumor cells to anoikis is an important mechanism through which TM1 exerts tumor suppression. Comparison of TM1 and TM2 proteins. TM1 and TM2 share extensive sequence homology except in the sequence coded by two alternatively spliced exons (amino acids 189-213 and 258-284). The asterisks identify unique cysteine residues in TM1 (cys 35) and TM2 (cys 190). (b) TM2 is not a tumor suppressor of breast cancer cells: MCF-7 cells were transfected to restore the expression of TM2, and stably selected cells were tested for TM2 expression using a commercial antibody (TM311, Sigma). Unmodified MCF-7 cells, empty vector transduced cells (MCF-7/V), TM2 and TM1 expressing MCF-7 cells were used in the immunoblotting experiment (top). Parental and TM2 expressing MCF-7 cells were cultured under anchorage-independent conditions (bottom). (c) Adenoviral transduction of TM1 suppresses anchorage-independent growth of MCF-7 cells: control and TM1 expressing adenoviruses were used to infect MCF-7 cells at 50% efficiency for 24 h, and then 2 Â 10 4 cells were plated on soft agar. Colony formation was monitored and the GFP-expression was recorded. TM1 expressing cells did not grow, as evidenced by lack of GFP signal, while the control vector transduction yielded a large number of GFP-positive colonies. Images were captured at Â 10 magnification using FITC cube. The bright field images are not shown. Results of a representative experiment are shown
Discussion
The present work demonstrates that downregulation of TM1 expression occurs in invasive breast cancers, and that restoration of TM1 expression induces anoikis in breast cancer cells. Loss of TM1 expression is likely to destabilize microfilament architecture, and render breast tumor cells resistant to anoikis. These changes may facilitate, invasion and increased survival of tumor cells as they leave their primary locations and become malignant. Thus, suppression of TM1 may promote cytoskeletal disorganization and confer a growth advantage to the neoplastic cells.
The high-M r TMs, including TM1, are abundantly expressed in the smooth muscle cells of the vasculature (Figures 2b and 3b) (Pittenger et al., 1994) . Furthermore, TM1 is expressed in fibroblasts, smooth muscle and epithelial cells (Prasad et al., 1991; Pittenger et al., 1994) , which complicates accurate quantification of TM1 in tissues by biochemical methods. Accordingly, other researchers have reported a modest decrease in high-M r TMs in primary breast tumors, and an increase in TM1 expression in the metastatic tumors (Franzen et al., 1996 (Franzen et al., , 1997 . Similarly, a preliminary report indicates variable expression of TMs in prostate tumors (Ahram et al., 2002) . Therefore, we employed in situ hybridization and isoform-specific antibodies in immunohistochemistry, and have demonstrated that TM1 expression is downregulated in breast tumors.
TM1 expression, however, appears to be more variable in other common malignancies such as colon and lung cancer cell lines (data not shown). It is relevant to note that enhanced expression of either TM1, or other TMs in ras-transformed RIE cells has no effect on either cell growth or cytoskeletal organization (Shields et al., 2002) . Therefore, it appears that TM1 effects may Downregulation of TM1 appears to be one of the most common and yet remarkable changes in breast cancer. In addition to TM1, other class II tumor suppressors such as NES1 ) and HME1 (14-3-3s) Umbricht et al., 2001) are also profoundly downregulated in a majority of breast cancers. Another actin-binding protein, has been quantitated. These samples do not contain any significant amount of apoptotic DNA gelsolin, which severs F-actin and involved in dynamic remodeling of actin filaments, is also widely suppressed in breast tumors (Asch et al., 1996; Mielnicki et al., 1999) .
Gross rearrangements in TM1 gene in breast tumors have not been detected (data not shown). Recent experiments with cultured breast cancer cell lines reveal that TM1 is silenced by epigenetic mechanisms involving gene methylation and histone deacetylation, which suggest that epigenetic mechanisms may regulate TM1 expression in tumors . Thus, along with retinoic acid receptor (Sirchia et al., 2000) , estrogen receptor and E-cadherin (Nass et al., 2000 ), 14-3-3s (Ferguson et al., 2000 and NES1 ), TM1 gene is also turned off epigenetically during malignant transformation. It is interesting to note that while mutations in aTMs cause familial hypertrophic cardiomyopathy (Michele and Metzger, 2000) and nemaline myopathy (Donner et al., 2002) , the epigenetic mechanisms (Yang et al., 2001) contribute to the loss of b TM gene function in neoplastic cells. However, fusions between low-M r TMs and protein kinases such as trk receptor (Mitra et al., 1987; Coulier et al., 1989) and anaplastic lymphoma kinase (ALK) (Meech et al., 2001) have been reported to be associated with malignant transformation. A transformation-specific low-M r TM isoform is reported to be expressed in colon tumors, but not in normal colonic epithelia (Lin et al., 2002) .
While changes in the expression and activities of several key focal adhesion proteins, such as FAK (Xu et al., 2000) , ILK (Persad et al., 2000) and Src (Coll et al., 2002; Windham et al., 2002) , are implicated in anoikis, resensitization of breast cancer cells to anoikis by TM1, a microfilament-associated protein, is novel. Thus, TM1, like other tumor suppressors such as PTEN (Lu et al., 1999) , DOC/hab (Wang et al., 2001) induces anoikis. Further investigations are underway to elucidate the molecular mechanisms of TM1-induced anoikis.
Materials and methods

Cell lines and reagents
Culture conditions for untransformed MCF10A, and the transformed MCF-7 and MDA MB 231 cells were previously described (Prasad et al., 1992) . A full-length TM1 cDNA clone (Prasad et al., 1991) was subcloned into pGEM3 vector (Promega) to generate 'antisense' and 'sense probes'. The RNA probes were labeled with [ 35 S]UTP by standard techniques for in situ hybridization. TM1 cDNA was cloned into pAdTrack CMV plasmid and recombined with the viral backbone pAdEasy-1 vector, and transfected into HEK293 cells (He et al., 1998) . TM2 (Braverman et al., 1996) was subcloned into pIRES2-EGFP plasmid (Clontech), and MCF-7 cells were transfected with the recombinant plasmid to coexpress GFP via an IRES sequence located downstream of the cloned TM2 cDNA.
A polyclonal pan-TM antibody that recognizes multiple TM proteins including TM1 has been previously described (Bhattacharya et al., 1990; Prasad et al., 1993; Mahadev et al., 2002) . This antibody recognizes high-M r TMs more avidly, although it reacts with low-M r proteins, as well. To detect TM1 specifically, we have generated several antipeptide antibodies and have determined them to be specific for TM1 Mahadev et al., 2002) . We have used one of the antibodies in immunofluorescence analyses to determine TM1 expression.
Tissue specimens
Aliquots of normal breast and tumor samples were obtained from patients undergoing surgery for their disease, through the Tumor Bank of Wake Forest University School of Medicine, Winston-Salem, NC, under the approval of the Institutional Review Board. Tissue samples (via mastectomy or lumpectomy) were collected within 60 min of surgery, fixed for 48 h in 10% phosphate-buffered formalin (pH 7.4) at room temperature, washed in 70% ethanol, embedded in paraffin, and cut into 5 mm sections for in situ hybridization, H&E staining and immunostaining. We have analysed a total of 25 breast tumors and their characteristics are given in Table 2 .
Tissue culture cells with known TM protein profiles were trypsinized and fixed in 4% paraformaldehyde and washed in 98% ethanol followed by a brief wash with a mixture of 98% ethanol and ether (1 : 1 v/v). The cell pellet was dried and embedded in paraffin. Sections (5 mm) were cut and used in in situ hybridization and immunofluorescence experiments. These sections were used to test and validate the screening methods.
In situ hybridization
To detect TM1 mRNA, in situ hybridization was performed using a method described by Wilcox et al. with some modifications (http://www.emory.edu/WILCOX). The formalin-fixed, paraffin-embedded tissue sections were deparafinized and hydrated, and processed for in situ hybridization as previously described (Mondy et al., 1997) . For quantitation of TM1 mRNA signal, nonoverlaping images were imported into an image analysis program essentially as described (Mondy et al., 1997) . Corresponding areas from parallel sections probed for nonspecific hybridization were subtracted. Results from each sample were averaged, and comparisons were made between the tumor and normal area.
Immunocytochemical analysis of TM expression in breast tumors
Deparaffinized tissue specimens were employed for immunofluorescence using TM1-specific antibody or pan-TM-antibody as the primary antibody. Serial 5-mm-thick tissue sections were subjected to immunofluorescence staining for detection of TM1, or multiple TMs as described previously (Shah et al., 2001; Mahadev et al., 2002) . For control purposes, samples were processed in parallel except with the omission of the primary antibody. Anti-rabbit immunoglobulin antibody conjugated with Texas Red was used as the secondary antibody (Molecular Probes) followed by counterstaining with 10 ng/ml DAPI (in methanol w/v) to visualize the nuclei and to identify the tissue architecture. Microscopic analysis was performed using a Â 25 Neofluar oil objective. Microscopic fields were captured with a Zeiss Axiocam camera, keeping the gain and exposure constant. Autofluorescence of tissue sections was observed using green fluorescence (FITC) channel, which did not interfere with the specific signal. TM1 expression was determined by quantifying the luminosity of the images using Adobe Photoshop (version 6.0) with the magic wand tool and the histogram function.
Cell cycle and anoikis experiments
Cell cycle analyses using propidium iodide and BrdU were carried out as described (Darzynkiewicz et al., 2001) . Briefly, cells were labeled for 1 h with BrdU (Sigma) at 20 mm concentration, harvested and fixed. Cells were reacted with anti-BrdU antibody (Becton-Dickinson) followed by incubation with FITC-conjugated second antibody (Sigma). Finally, the samples were stained with 20 mg/ml propidium iodide and subjected to flow cytometric analysis. S-phase fraction was calculated as a percentage of Brdu containing cells in the total cells (combined fractions of propidium iodide and BrdU containing cells).
Anoikis experiments were carried out on polyHEMA (Sigma) coated dishes (final concentration 10 mg/ml, w/v in ethanol, two applications) as described by Zhu et al. (2001) . Cells were cultured in serum-free, 1% BSA containing medium. Cells were harvested and collected by Cyospin, and stained with 10 ng/ml DAPI to visualize nuclei. The cells were photographed using a Zeiss Axioplan 2 microscope (Carl Zeiss, Germany) with a Â 100 objective, and a Zeiss Axiocam camera. Images were imported into Adobe Photoshop. To calculate the percent cells undergoing anoikis, several image fields were photographed and the percent apoptotic nuclei were counted. The DNA content in subG 0 -G 1 fraction was calculated as flow cytometry (Darzynkiewicz et al., 2001 ).
Other methods
Northern blot analysis was used to quantify TM1 mRNA expression (Mahadev et al., 2002) . For protein analyses, cultured cells were solubilized in lysis buffer (Mahadev et al., 2002) . The membranes were probed with TM1-specific antibody or pan-TM antibody and a-tubulin antibody Mahadev et al., 2002) . Anchorage-independent growth was measured by plating 2 Â 10 4 cells on soft agar plates and culturing for 2-3 weeks. In experiments involving adenoviral infections, cells were infected for 24 h and then plated on soft agar. To transduce TM1, the recombinant virus at 180 MOI was used and the control virus was used at 100 MOI to achieve about 50% infectivity of MCF-7 cells, as measured by GFP expression. Statistical analyses were performed using PROC MIXED within the Statistical Analysis System for personal computers (SAS Institute, Cary, NC, USA).
